

INTERNATIONAL JOURNAL OF EXPERIMENTAL AND BIOMEDICAL RESEARCH

Published by Pharma Springs Publication Journal Home Page: <u>https://pharmasprings.com/ijebr</u>

A new method of development and validation of Methanesulfonic acid ester (Methyl, Ethyl) impurity content in dabigatran etexilate mesylate by GC MS

Shaik Mohammed Ameen Basha*, S Shahidha Bee

Department of Pharmaceutical Analysis, Safa College of Pharmacy, B Tandrapadu, Kurnool, Andhra Pradesh - 518007

| Article History: | Abstract (|
|--|--|
| Received on: 16 Apr 2024 Revised on: 11 Jun 2024 Accepted on: 12 Jun 2024 | We attempted to establish a method for estimating methane sulfonic acid methyl or ethyl ester in the dabigatran etexilate Mesylate in bulk and pharmaceutical dosage form. Dabigatran is an anticoagulant used in deep vein thrombosis and lung thrombosis. Methane sulfonic acid and ethyl sulfonic acid are DNA ethylating agents and genotoxic. These compounds can be estimated using the GC MS method using Helium as a carrier gas, and the compounds are estimated to be at 79 and 400 masses. The 60% methanol is used as diluent and blank. The method is validated as per the |
| Keywords: | procedures of ICH, and all the validation parameters are within the |
| Dabigatran, Methane sulphonic acid, Methyl ester, Ethyl Ester, GC-MS | acceptable limit of the impurities guidelines, as stated in the Q4 section. The different batches were analyzed using the same technique, and no impurities were found; hence, the batches were passed. |

*Corresponding Author

Name: Shaik Mohammed Ameen Basha Phone: +91 9133088767 Email: ameenbadshah143@gmail.com

eISSN: 2583-5254 DOI: <u>https://doi.org/10.26452/ijebr.v3i3.638</u>

| 回然回 | |
|------|---|
| 2322 | Ş |
| 市田中 | |

Production and hosted by Pharmasprings.com © 2024 | All rights reserved

INTRODUCTION

Dabigatran is an ant-clotting agent used to prevent stroke and harmful blood clots in deep veins of the legs and lungs. If a person is suffering from atria fibrillation, that means irregular heartbeat [1]. Hence, Dabigatran is used to treat blood clots in the deep veins of the legs and deep vein thrombosis or in the lungs. It is a pulmonary embolism and reduces the risk of these clots. Dabigatran etexilate is an oral prodrug and hydrolyzed to convert active Dabigatran, and the drug was approved by the FDA in 2010 [2]. The significant brand available is Pradaxa by Boehringer Ingelheim Pharmaceutical Limited.

Ethyl methanesulfonic acid has been used to induce mutations in mouse embryonic fibroblasts, yeast, and human lymphocytes. Ethyl methanesulfonate is a DNA ethylating agent, mutagenic to plants and animals, and carcinogenic in mammals [3]. It has been used as a model alkylating agent in studies of DNA repair processes. EMS induces base substitutions of guanine-cytosine (G/C) to adenine-thymine (A/T). EMS also generates point mutations and single nucleotide polymorphisms in genomes [4]. EMS is a potential chemical mutagen used to induce mutations in rice, wheat, and Arabidopsis thaliana. Methyl Methanesulfonic acid (MMS) methyl Mesylate is an alkylating agent and carcinogen. It is also a suspected reproductive toxicant and also a skin/ sense organ toxicant. It is used in cancer treatment [5].

MATERIALS AND METHODS

MATERIALS

Dabigatran Pure drug, Ethyl Methanesulfonic acid and Methyl Methanesulfonic acid, Helium, Nitrogen, Methanol, Water HPLC grade.

METHODS

Preparation of Standard and Sample solutions

Methanesulfonic acid methyl ester and ethyl ester standard solution

Transfer 10 mg of each methane sulfonic acid methyl and ethyl ester into a 10 ml of the volumetric flask, fill the flask with diluent, and Transfer 100 μ l of methane sulfonic acid methyl and ethyl ester stock solution into a 10 ml of volumetric flask and makeup to the mark with the same diluents [6]. The above solution contains about five ppm of methyl and ethyl ester concerning 50 mg/ml of sample concentration [7].

Preparation of sample solution: Transfer 250 mg of sample into a 5 ml volumetric flask and fill the flask with diluent. The final concentration of the sample and standard were prepared at five ppm [8].

Optimization:

The GC MS Instrument is Made Agilent and made of MS 5975C triple-axis detector with 7890A, column DB-5ms, and a column length of 30 mts with a Diameter of 0.25 mm SCOT column is used; the silicon solid support, the temperature of the Injection port is maintained at 140°c used the Helium as carrier gas and Mobile phase comprise of H₂ and O₂ with a ration of 40 and 400 ml/min. The detector temperature is 250oC, the flow rate maintains 0.8 ml/min, and the flow rate is maintained at 0.8 ml/min. The Mass Spectroscopy uses a Quadruple mass analyzer and Ion/Dwell in groups 79.0, 400 ml, and 80.0, 400 ml [9][10][11][12].

Precision

The precision is measured by injecting six replicate injections of similar concentrations of EMS and MMS into a GC MS.

Precision LOD

LOD level methane sulfonic acid methyl and ethyl ester standard solutions preparations made by dissolving 10 μ l of methane sulfonic methyl ester and ethyl ester stock solution transferred into a 10 ml volumetric flask containing 5 ml of diluent, dilute to volume with diluent and mixed well [Table 1].

Precision of LOQ level

LOQ solution is prepared by transferring 33 μ l of methane sulfonic acid methyl ester and ethyl ester stock solutions into a 10 ml volumetric flask containing 5 ml of diluent and diluting the flask up to the volume with the same solvent and mixing for a few minutes. This solution is injected six times to perform the LOQ level precision [Table 2].

Accuracy at LOQ level

Continue from the precision at the LOQ level, and the last three injections from the precision at the LOQ level were taken for accuracy at LOQ level calculations. Individual stock solutions of methane sulfonic acid methyl and ethyl ester were used.

Accuracy at LOQ level

Continue from the precision at the LOQ level. The last three injections at the LOQ level were taken for accuracy at LOQ level calculations, and individual stock solutions were used: methane sulfonic acid methyl and ethyl ester.

Sample + 50% standard solution

Weight accurately 250 mg of sample to be examined into a 5 ml volumetric flask containing 2 ml of 50% standard solution and diluted to volume with diluent and mixed well.

Sample + 100% LOQ level standard solution

Weigh accurately 250 mg of sample to be examined into a 5 ml volumetric flask containing 2 ml of LOQ standard solution and diluted to volume with diluent and mixed well.

Sample + 150% standard solution

Weigh accurately 250 mg of sample to be examined into a 5 ml volumetric flask containing 2

Table 1 Precision and Accuracy

| | MSA Methyl Ester | | | MMS Ethyl Ester | | r |
|---------------------------------|------------------|-----|-----|-----------------|----|-----|
| | Mean | SD | RSD | Mean | SD | RSD |
| Precision | 2089 | 4.3 | 2.1 | 1586 | 59 | 3.7 |
| LOD s/n | 2.3 | - | - | 3.1 | - | - |
| LOQ s/n | 9.6 | - | - | 9.8 | - | - |
| Precision at LOD (0.5 ppm) | 815 | 28 | 3.4 | 669 | 26 | 3.9 |
| Precision at LOQ (1.7 ppm) | 663 | 18 | 2.7 | 482 | 18 | 3.7 |
| Accuracy at LOQ 50% - Recovery | 99 | - | - | 98 | - | - |
| Accuracy at LOQ 100% - Recovery | 103 | - | - | 101 | - | - |
| Accuracy at LOQ 150% - Recovery | 99 | - | - | 99 | - | - |
| Average Recovery | 99 | - | - | 99 | - | - |
| Range | 663 | 18 | 2.7 | 482 | 18 | 3.7 |


Table 2 Linearity


| Concentration (%) of methane sulfonic acid methyl ester. | Area | Concentration (%) of methane sulfonic acid ethyl ester. | Area |
|--|--------|---|--------|
| 33 | 687 | 33 | 468 |
| 50 | 1044 | 50 | 844 |
| 80 | 1645 | 80 | 1290 |
| 90 | 1831 | 90 | 1442 |
| 100 | 2093 | 100 | 1625 |
| 110 | 2226 | 110 | 1858 |
| 120 | 2409 | 120 | 1977 |
| 150 | 3069 | 150 | 2489 |
| Slope | 20.42 | Slope | 16.45 |
| Y-intercept | 29 | Y-intercept | -63 |
| Correlation coefficient | 0.9994 | Correlation coefficient | 0.9987 |

ml of 150% standard solution and diluted to volume with diluent and mixed well.

Linearity

The various concentrations were prepared from 50% to 150% and injected into the optimized conditions of GC. The correlation coefficient and other conditions were measured [Table 2].







RESULTS AND DISCUSSION

Stability for sample and standard solutions

The chromatographic conditions and system settings are maintained per the requirements [Table 3. 4, 5]. The standard solution of about five ppm and the sample solution of approximately five ppm are prepared, and the stability will be verified for both the sample and standard solutions.

SUMMARY AND CONCLUSION

Prepare a standard solution of 5 ppm each and approximately similar sample concentration using the same mobile phase as 60% methanol. The method is validated for its precision, LOD and LOQ, accuracy, robustness, and ruggedness were performed. The linearity of the experiment is done by injecting 33% to 150% of the original concentration level. The slope correlation coefficients were plotted and found to be within the acceptable limit. The accuracy of the experiment is checked to ensure the exactness of the procedure. This is done by injecting 50%, 100%, and 150% levels of standard solution added to the blank or sample solution. In all the cases, the percentage of recovery was between 98 – 102% for both methane sulfonic acid methyl

Table 3 Standard solution stability

| S.No | Parameter | Injection | Acquired date & time | MSAME | MASEE |
|------|--------------------|---------------|----------------------|-------|-------|
| 1 | Solution stability | Start (0 Hrs) | 20/11/2023 18:52 | 1845 | 1006 |
| 2 | | End (~8 Hrs) | 21/11/2023 03:14 | 1796 | 911 |

Table 4 Sample solution stability

| S.No | Parameter | Injection | Acquired date & time | MSAME | MASEE |
|------|-----------------|---------------|----------------------|-------|-------|
| 1 | Sample Solution | Start (0 Hrs) | 20/11/2023 20:52 | 0 | 0 |
| 2 | stability | End (~14 Hrs) | 21/11/2023 10:45 | 0 | 0 |

Table 5 Spiking solution stability

| S.No | Parameter | Injection | Acquired date & time | MSAME | MASEE |
|------|----------------------------|---------------|----------------------|-------|-------|
| 1 | Spiking Solution stability | Start (0 Hrs) | 20/11/2023 20:35 | 1855 | 1022 |
| 2 | | End (~7 Hrs) | 21/11/2023 03:31 | 1728 | 982 |

The experiment's precision is achieved by injecting the six preparations of the standard with the optimized chromatography conditions. The average peak area, standard deviation, and relative standard deviation were calculated. The results were found to be 2.1 and 3.7respectively for MMS and MES. The % RSD for methane sulfonic acid methyl ester and ethyl ester should not be more than 15.0 based on the above results, revealing that the system meets the required system suitability criteria.

The detection limit is carried out using the signalto-noise ratio method, and the LOD concentrations of MMS and MES are 0.5 and 0.5 ppm, respectively. The LOQ concentrations of MMS and MES are 1.7 and 1.7 ppm, respectively. We followed precision to the LOQ level by injecting 1.7 ppm of MMS and MES into the chromatography system six times. The average area, SD, and RSD are compared with acceptable criteria. The same experiment was also carried out for different batches to find the LOQ level of MMS and MES, and there were no detection levels in the batches. ester and methane sulfonic acid ethyl ester. The results proved that the experiment accurately determines specified impurities in the Dabigatran in API and formulations.

The range of the MMS and MES can be done by injecting six replicate injections of LOQ level and 150% level of the standard into the specified experimental conditions and verifying their reliability with the acceptable criteria. Finally, a stability study is conducted to see the 0 hours to up to 14 hours of the solution preparation if no degradation is detected. A different batch analysis was performed. From the data, we can conclude that the methane sulfonic acid methyl and ethyl ester were not detected in all batches of Dabigatran etexilate Mesylate.

ACKNOWLEDGEMENT

We want to express our profound appreciation to our management and principal. I am incredibly grateful to Safa College of Pharmacy, B Tandrapadu, Kurnool, Andhra Pradesh–518007, for their support, without which it would not have been possible to complete our research work.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Funding Support

The authors declare that they have no funding for this study.

REFERENCES

- [1] Lakshmi Hima Bindu MR, Angala Parameswari S, Gopinath C, et al. A Review on GC-MS and Method Development and Validation. International journal of pharmaceutical quality assurance, 2013;4(3):42-51.
- [2] Uber CP, Degaut Pontes FL, Gasparetto JC, De Francisco TM, Piantavini MS, Cardoso MA, Pontarolo R, et al. HPLC-MS/MS method for simultaneous quantifying vildagliptin, metformin, and metforminrelated compounds in tablets. International journal of pharmacy and pharmaceutical sciences. 2014;6(11):370–372.
- [3] Kuo CW, Liaw WJ, Huang PW, Pao LH, et al. A Rapid and Sensitive HPLC Method for Determination of Roxatidine in Human Plasma. Journal of food and drug analysis. 2008;16(3):1-7.
- [4] Trivedi MK, Jana S, et al. Evaluation of the Impact of Consciousness Energy Healing Treatment on the Structural Properties and Isotopic Abundance Ratio of Vitamin C using LC-MS, GC-MS, and NMR Spectroscopy. Annals of chromatography and separation techniques. 2016;2(2):1021.
- [5] Ali MB, Attia M, Bellili N, Fattouch S, et al. Development and Validation of an RP-HPLC Method for Simultaneous Determination of Betamethasone and Benzoate Sodium in Oral Liquid Pharmaceutical Formulation. Indian journal of pharmaceutical sciences. 2016;78(3):413-416.
- [6] Vinzuda DU, Sailor GU, Sheth NR, et al. RP-HPLC Method for Determination of Valsartan in Tablet Dosage Form. International Journal of chem. Tech research. 2010;2(3):1461-1467.

- [7] Hepsebah NJR, Ashok Kumar A, et al. Spectrometric Dissolution Method For Dabigatran Etexilate Mesylate Capsules. World journal of pharmacy and pharmaceutical sciences. 2018;7(4):1277-1290.
- [8] Raghubabu K, Mohan Rao N, Ramu BK, Ramdas C, et al. Solifenacin succinate estimation in bulk and pharmaceutical preparations by visible spectrophotometry. An Indian journal of analytical chemistry. 2014;14(7): 0974-7419.
- [9] Antovic JP, Skeppholm M, Eintrei J, Eriksson Boija E, Soderblom L, Marie Norberg E, Onelov L, Ronquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmstrom RE, et al. Evaluation of coagulation assays versus LC-MS/MS for determining dabigatran concentrations in plasma. European journal of clinical pharmacology. 2013;69(11):1875-1881.
- [10] Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, Hjemdahl P, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thrombosis and Haemostasis. 2013;110(3):543-549.
- [11] Sowjanya P, Subashini D, Lakshmi Rekha K, et al. Analytical Validation Parameters. Research and Reviews: Journal of Pharmaceutical Analysis. 2015;4(1):65-74.
- [12] Balaji N, Sivaraman VR, Neeraja P, et al. GC Quantification of Residual hexylmethane sulfonate in Dabigatran etexilate mesylate. IOSR journal of applied chemistry. 2012;2(6):48 – 51.

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial- Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.



© 2024 Pharma Springs Publication